RUNX1 and myelodysplastic syndrome: Approximately 25%–50% of individuals with RUNX1-FPDMM will develop malignancy (9, 13, 14), mainly MDS and AML and less frequently acute lymphoblastic leukemia (ALL) or lymphoma or other hematologic malignancies.